



General Assembly

**Amendment**

February Session, 2024

LCO No. 4165



Offered by:

SEN. MARONEY, 14<sup>th</sup> Dist.  
REP. D'AGOSTINO, 91<sup>st</sup> Dist.  
SEN. CICARELLA, 34<sup>th</sup> Dist.  
REP. RUTIGLIANO, 123<sup>rd</sup> Dist.

To: Subst. Senate Bill No. 133

File No. 89

Cal. No. 78

**"AN ACT CONCERNING REGULATION OF PRESCRIPTION DRUGS  
AND RELATED PROFESSIONS."**

1 Strike everything after the enacting clause and substitute the  
2 following in lieu thereof:

3 "Section 1. Section 20-571 of the 2024 supplement to the general  
4 statutes is repealed and the following is substituted in lieu thereof  
5 (*Effective October 1, 2024*):

6 As used in this chapter and sections 2 to 4, inclusive, of this act, unless  
7 the context otherwise requires:

8 (1) "Administer" or "administration" means the direct application of  
9 a drug or device to the body of a patient or research subject by injection,  
10 inhalation, ingestion or any other means;

11 (2) "Advanced pharmacy technician" means a pharmacy technician

12 who: (A) Receives from the department a designation (i) under section  
13 2 of this act, and (ii) which permits delegation of certain pharmacist  
14 responsibilities to the pharmacy technician; and (B) is qualified in  
15 accordance with section 2 of this act;

16 [(2)] (3) "Automated prescription dispensing machine" means a  
17 device and associated software operated by a pharmacy or a pharmacy  
18 that is registered as a nonresident pharmacy pursuant to section 20-627,  
19 in a nursing home or skilled nursing facility licensed pursuant to  
20 sections 19a-490 and 19a-491, that packages and labels patient-specific  
21 medication or multiple medications for the purposes of administration  
22 by a registered nurse or a licensed practical nurse based on a  
23 prescription that has completed [final] order entry verification  
24 performed by a [licensed] pharmacist;

25 [(3)] (4) "Care-giving institution" means an institution that provides  
26 medical services and is licensed, operated, certified or approved by the  
27 Commissioner of Public Health, the Commissioner of Developmental  
28 Services or the Commissioner of Mental Health and Addiction Services;

29 (5) "Clerk" means an individual who is: (A) Registered with the  
30 department, in accordance with section 3 of this act, to work in the area  
31 of a pharmacy or institutional pharmacy where controlled substances or  
32 other legend drugs are dispensed by, or under the supervision of, a  
33 pharmacist; (B) not employed or contracted by a pharmacy or  
34 institutional pharmacy solely to deliver dispensed drugs to patients off  
35 the premises of the pharmacy or institutional pharmacy; and (C) not  
36 involved in order entry, the dispensing process or preparing a  
37 prescription for final verification;

38 [(4)] (6) "Commission" means the Commission of Pharmacy  
39 appointed under the provisions of section 20-572;

40 [(5)] (7) "Commissioner" means the Commissioner of Consumer  
41 Protection;

42 (8) "Compatible drugs" means multiple drugs that are not adversely

43 impacted, whether chemically or physically, in constitution or quality  
44 by one another;

45 (9) "Compliance packaging" means packaging that: (A) Is prepared at  
46 a pharmacy to assist a patient in administering solid oral dosage forms  
47 of one or more drugs that have been prescribed for the patient; (B)  
48 divides the patient's drugs into a series of compartments or containers  
49 within one package according to (i) the directions for use, and (ii) the  
50 day and time such drugs are to be administered; and (C) is reusable or  
51 nonreusable;

52 ~~[(6)]~~ (10) "Compound" means to combine, mix or put together two or  
53 more ingredients pursuant to a prescription and includes the  
54 preparation of drugs or devices in anticipation of prescriptions based on  
55 routine, regularly-observed prescribing patterns;

56 ~~[(7)]~~ (11) "Correctional or juvenile training institution" means a  
57 facility for the detention or incarceration of persons convicted or  
58 accused of crimes or offenses or for training of delinquent juveniles,  
59 including those state facilities under the jurisdiction of the  
60 Commissioner of Correction, training schools for delinquent juveniles  
61 and any other facilities operated by the state or municipalities for such  
62 detention, incarceration or training;

63 ~~[(8)]~~ (12) "Device" means instruments, apparatuses and contrivances,  
64 including their components, parts and accessories, intended: (A) For use  
65 in the diagnosis, cure, mitigation, treatment or prevention of disease in  
66 humans or other animals; or (B) to affect the structure or any function of  
67 the body of humans or other animals, but does not mean contact lenses;

68 ~~[(9)]~~ (13) "Department" means the Department of Consumer  
69 Protection;

70 ~~[(10)]~~ (14) "Deprescribing" means the systematic process of  
71 identifying and discontinuing drugs in instances in which existing or  
72 potential harms outweigh existing or potential benefits within the  
73 context of an individual patient's care goals, current level of functioning,

74 life expectancy, values and preferences;

75 (15) "Direct supervision" means the supervision of pharmacy  
76 personnel, including, but not limited to, pharmacy interns, pharmacy  
77 technicians and advanced pharmacy technicians, by a pharmacist who:  
78 (A) Is physically present on the premises of the pharmacy or  
79 institutional pharmacy while (i) routine drug dispensing functions are  
80 being performed on such premises, and (ii) the pharmacy personnel  
81 who are under such pharmacist's supervision are physically present on  
82 such premises; and (B) conducts in-process and final performance  
83 checks;

84 [(11)] (16) "Dispense" means those acts of processing a drug or device  
85 for delivery or for administration for a patient pursuant to a prescription  
86 consisting of: (A) Comparing the directions on the label with the  
87 directions on the prescription to determine accuracy; (B) the selection of  
88 the drug or device from stock to fill the prescription; (C) the counting,  
89 measuring, compounding or preparation of the drug or device; (D) the  
90 placing of the drug or device in the proper container; (E) the affixing of  
91 the label to the container; and (F) the addition to a written prescription  
92 of any required notations. "Dispense" does not include the acts of  
93 delivering a drug or device to a patient or of administering the drug or  
94 device to the patient;

95 [(12)] (17) "Dispensing outpatient facility" means a facility operated  
96 by a [corporation] business entity or municipality which provides  
97 medical services to patients on an outpatient basis and which maintains  
98 stocks of drugs for dispensing of drugs on a regular basis to patients for  
99 use off the premises;

100 [(13)] (18) "Drug" means: (A) An article recognized in the official  
101 United States Pharmacopoeia, official Homeopathic Pharmacopoeia of  
102 the United States or official National Formulary, or any supplement to  
103 any of them; (B) an article intended for use in the diagnosis, cure,  
104 mitigation, treatment or prevention of disease in humans or other  
105 animals; (C) an article, other than food, intended to affect the structure

106 or any function of the body of humans or any other animal; and (D) an  
107 article intended for use as a component of any article specified in this  
108 subdivision, but does not include a device;

109 (19) "Final verification" means the last review that: (A) Is conducted  
110 to complete the dispensing process by verifying that the product to be  
111 dispensed conforms to the product ordered or prescribed by the  
112 prescribing practitioner; and (B) includes, at a minimum, comparing, for  
113 accuracy, the original prescription, the contents of the prescription label  
114 and the contents of the prescription container;

115 ~~[(14)]~~ (20) "Health care institution" means institution, as defined in  
116 section 19a-490;

117 ~~[(15)]~~ (21) "Health care institutional pharmacy" means an institutional  
118 pharmacy located within a health care institution;

119 ~~[(16)]~~ (22) "Institutional pharmacy" means that area within a care-  
120 giving institution or within a correctional or juvenile training  
121 institution, commonly known as the pharmacy, that is under the direct  
122 charge of a pharmacist and in which drugs are stored and dispensed;

123 ~~[(17)]~~ (23) "Legend device" means a device that is required by  
124 applicable federal or state law to be dispensed pursuant only to a  
125 prescription or is restricted to use by prescribing practitioners only or  
126 that, under federal law, is required to bear either of the following  
127 legends: (A) "RX ONLY" IN ACCORDANCE WITH GUIDELINES  
128 ESTABLISHED IN THE FEDERAL FOOD, DRUG AND COSMETIC  
129 ACT; or (B) "CAUTION: FEDERAL LAW RESTRICTS THIS DEVICE  
130 FOR USE BY OR ON THE ORDER OF A LICENSED VETERINARIAN.";

131 ~~[(18)]~~ (24) "Legend drug" means a drug that is required by any  
132 applicable federal or state law to be dispensed pursuant only to a  
133 prescription or is restricted to use by prescribing practitioners only, or  
134 means a drug that, under federal law, is required to bear either of the  
135 following legends: (A) "RX ONLY" IN ACCORDANCE WITH  
136 GUIDELINES ESTABLISHED IN THE FEDERAL FOOD, DRUG AND

137 COSMETIC ACT; or (B) "CAUTION: FEDERAL LAW RESTRICTS THIS  
138 DRUG FOR USE BY OR ON THE ORDER OF A LICENSED  
139 VETERINARIAN.";

140 [(19)] (25) "Medical device and oxygen provider" means a person who  
141 distributes devices or oxygen pursuant to a medical order or  
142 prescription, except if such person already maintains an active  
143 pharmacy license;

144 [(20)] (26) "Medication reconciliation" means a process of comparing  
145 the medications a patient is taking and should be taking with newly  
146 ordered medications: (A) For the purpose of addressing duplications,  
147 omissions and interactions and the need to continue current  
148 medications; and (B) by looking at information such as the medication  
149 name, dose, frequency, route of administration and purpose;

150 [(21)] (27) "Nonlegend device" means a device that is not a legend  
151 device;

152 [(22)] (28) "Nonlegend drug" means a drug that is not a legend drug;

153 [(23)] (29) "Nonresident pharmacy" has the same meaning as  
154 provided in section 20-627;

155 (30) "Order entry" means the process by which prescription data is  
156 entered into an electronic data processing system used by a pharmacy  
157 to record dispensed products, which prescription data shall include, but  
158 need not be limited to: (A) Patient demographic data; (B) drug name and  
159 strength; (C) drug quantity; (D) directions for use; and (E) the number  
160 of authorized refills, including, but not limited to, any use of "PRN" or  
161 "ad lib" in lieu of a specific number of authorized refills;

162 (31) "Patient" means a human or other animal who receives any  
163 health care service provided by a health care provider, including, but  
164 not limited to, a pharmacist, for: (A) The purpose of curing, diagnosing,  
165 mitigating, palliating, preventing, screening for or treating a past,  
166 current or future medical condition; or (B) any research-related purpose;

167 [(24)] (32) "Person" means an individual, corporation, business trust,  
168 estate trust, partnership, association, joint venture or any other legal or  
169 commercial entity;

170 [(25)] (33) "Pharmacist" means an individual who is licensed to  
171 practice pharmacy under the provisions of section 20-590, 20-591, 20-592  
172 or 20-593, and who is thereby recognized as a health care provider by  
173 the state of Connecticut;

174 [(26)] (34) "Pharmacy" means a place of business where drugs and  
175 devices may be sold at retail and for which a pharmacy license has been  
176 issued to an applicant under the provisions of section 20-594;

177 [(27)] (35) "Pharmacy intern" means an individual registered under  
178 the provisions of section 20-598;

179 [(28)] (36) "Pharmacy technician" means an individual who is  
180 registered with the department and qualified in accordance with section  
181 20-598a, as amended by this act;

182 [(29)] (37) "Polypharmacy" means the use of multiple drugs by a  
183 patient, including any medication that is inappropriate or not medically  
184 necessary, such as those not indicated, not effective or constituting a  
185 therapeutic duplication;

186 [(30)] (38) "Practice of pharmacy" or "to practice pharmacy" means the  
187 sum total of knowledge, understanding, judgments, procedures,  
188 securities, controls and ethics used by a pharmacist to assure optimal  
189 safety and accuracy in the distributing, dispensing and use of drugs and  
190 devices;

191 [(31)] (39) "Prescribing practitioner" means an individual licensed by  
192 the state of Connecticut, any other state of the United States, the District  
193 of Columbia, the Commonwealth of Puerto Rico or any territory or  
194 insular possession subject to the jurisdiction of the United States who is  
195 authorized to issue a prescription within the scope of the individual's  
196 practice;

197 [(32)] (40) "Prescription" means a lawful order of a prescribing  
198 practitioner transmitted either orally, in writing or by electronic means  
199 for a drug or device for a specific patient;

200 (41) "Redispense" means to reprocess any drug: (A) That is prescribed  
201 to a patient, was previously dispensed in compliance packaging and has  
202 been returned to the dispensing pharmacy due to a change in the  
203 patient's prescription or prescriptions; (B) by comparing the directions  
204 on the prescription label with the directions on the prescription to  
205 ensure accuracy; (C) by selecting such drug from the returned  
206 compliance packaging or from stock to fill a current prescription for  
207 such drug; (D) by counting such drug and placing such drug in the  
208 proper container or compliance packaging compartment for return to  
209 the patient; and (E) by affixing to the container or compliance packaging  
210 a label containing (i) the prescription information set forth in section 20-  
211 617 and required under section 4 of this act, and (ii) any additional  
212 notations required due to the prescribing practitioner's directions;

213 [(33)] (42) "Sale" includes barter, exchange or gift or offer and each  
214 such transaction made by a person whether as principal proprietor,  
215 agent, servant or employee;

216 [(34)] (43) "Substitute" means to dispense without the prescribing  
217 practitioner's express authorization a different drug product than the  
218 drug product prescribed;

219 [(35)] (44) "Third-party logistics provider" means a person who  
220 distributes drugs, devices or cosmetics while taking possession of the  
221 drugs, devices or cosmetics but who does not take title of the drugs,  
222 devices or cosmetics;

223 [(36)] (45) "Virtual manufacturer" means a person who engages in the  
224 manufacture of drugs, devices or cosmetics for which such person: (A)  
225 Owns the new drug application or abbreviated new drug application  
226 number, if a prescription drug; (B) owns the unique device identification  
227 number, as available, for a prescription device; (C) contracts with a  
228 contract manufacturing organization for the physical manufacture of



229 the drugs, devices or cosmetics; (D) is not involved in the physical  
230 manufacture of the drugs, devices or cosmetics; and (E) at no time takes  
231 physical possession of or stores the drugs, devices or cosmetics; and

232 [(37)] (46) "Virtual wholesale distributor" means a person who  
233 facilitates or brokers the transfer of drugs, devices or cosmetics without  
234 taking physical possession of the drugs, devices or cosmetics.

235 Sec. 2. (NEW) (*Effective October 1, 2024*) (a) (1) No pharmacy  
236 technician may perform the duties of an advanced pharmacy technician  
237 in this state, including, but not limited to, dispensing or redispensing to  
238 patients compatible drugs in compliance packaging under section 4 of  
239 this act, unless such pharmacy technician has applied for and received  
240 an advanced pharmacy technician designation in accordance with the  
241 provisions of this section.

242 (2) Each advanced pharmacy technician designation issued under  
243 this section shall be issued in a form and manner prescribed by the  
244 commissioner, shall be valid for one year and may be renewed for  
245 successive one-year periods upon submission of a complete application  
246 and payment of the renewal fee required in section 20-601 of the general  
247 statutes, as amended by this act.

248 (b) The department shall issue an advanced pharmacy technician  
249 designation to a pharmacy technician who:

250 (1) Submits to the department, in a form and manner prescribed by  
251 the commissioner, (A) a complete application for designation as an  
252 advanced pharmacy technician, and (B) the application fee required in  
253 section 20-601 of the general statutes, as amended by this act;

254 (2) Is actively registered and qualified as a pharmacy technician in  
255 accordance with section 20-598a of the general statutes, as amended by  
256 this act;

257 (3) Was continuously registered as a pharmacy technician in  
258 accordance with section 20-598a of the general statutes, as amended by

259 this act, for the three-year period immediately preceding the date on  
260 which such pharmacy technician applies for an advanced pharmacy  
261 technician designation under this section;

262 (4) Continuously held a certification from the Pharmacy Technician  
263 Certification Board, or any other equivalent pharmacy technician  
264 certification program approved by the department, for the three-year  
265 period immediately preceding the date on which such pharmacy  
266 technician applies for an advanced pharmacy technician designation  
267 under this section, and maintains such certification in good standing;

268 (5) Successfully completed (A) an educational course, during the one-  
269 year period immediately preceding the date on which such pharmacy  
270 technician applies for an initial advanced pharmacy technician  
271 designation under this section, that (i) is accredited by the Accreditation  
272 Council for Pharmacy Education or another appropriate national  
273 accrediting body, or (ii) the commissioner, in the commissioner's  
274 discretion, deems equivalent to an educational course accredited as set  
275 forth in subparagraph (A)(i) of this subdivision, and (B) a competency  
276 assessment performed by a pharmacist in accordance with requirements  
277 established by the commissioner in regulations adopted pursuant to  
278 subsection (e) of this section;

279 (6) Is employed by a pharmacy or institutional pharmacy that  
280 satisfies the requirements established in subsection (d) of this section;  
281 and

282 (7) (A) Works under the direct supervision of a pharmacist who  
283 satisfies the requirements established in subdivision (1) of subsection (c)  
284 of this section; or

285 (B) Is supervised (i) in the manner set forth in section 20-609a of the  
286 general statutes, or (ii) in any manner approved by the commissioner or  
287 commission.

288 (c) (1) The pharmacist who directly supervises an advanced  
289 pharmacy technician may delegate to the advanced pharmacy

290 technician:

291 (A) The pharmacist's authority to perform final verifications,  
292 provided the pharmacy or institutional pharmacy that employs such  
293 advanced pharmacy technician satisfies the requirements established in  
294 subsection (d) of this section;

295 (B) The pharmacist's authority to administer vaccines in accordance  
296 with the provisions of section 20-633 of the general statutes, as amended  
297 by this act, and the regulations adopted pursuant to subsection (d) of  
298 said section; and

299 (C) The pharmacist's authority to administer COVID-19-related tests,  
300 influenza-related tests and HIV-related tests in accordance with the  
301 provisions of section 20-633f of the general statutes, as amended by this  
302 act, and the regulations adopted pursuant to subsection (g) of said  
303 section, except the pharmacist shall not delegate such pharmacist's  
304 responsibility to present the results of any such test to the patient.

305 (2) No pharmacist who makes any delegation to an advanced  
306 pharmacy technician under subdivision (1) of this subsection shall  
307 delegate to the advanced pharmacy technician any discretionary  
308 decision-making authority concerning the propriety of any drug in  
309 relation to a patient's medical condition or treatment plan.

310 (d) (1) The pharmacy or institutional pharmacy that employs an  
311 advanced pharmacy technician:

312 (A) Shall use bar code technology, or another technology approved  
313 by the department, to assist in dispensing drugs and confirm accuracy  
314 in dispensing; and

315 (B) Shall not permit the ratio of advanced pharmacy technicians to  
316 pharmacists physically present in the pharmacy premises or  
317 institutional pharmacy to exceed one advanced pharmacy technician to  
318 one pharmacist providing direct supervision, except such pharmacy or  
319 institutional pharmacy may deviate from such ratio if such deviation is

320 authorized by the commissioner or commission, including, but not  
321 limited to, in any regulation adopted by the commissioner pursuant to  
322 subsection (e) of this section. The commissioner or commission shall not  
323 provide for a ratio of pharmacy technicians to supervising pharmacists  
324 that is lower than three-to-one, and no advanced pharmacy technician  
325 shall be counted toward such ratio.

326 (2) If a pharmacy employs an advanced pharmacy technician, the  
327 pharmacy shall, in addition to satisfying the requirements set forth in  
328 subdivision (1) of this subsection, not allow the advanced pharmacy  
329 technician to perform any final verification under subparagraph (A) of  
330 subdivision (1) of subsection (c) of this section unless such advanced  
331 pharmacy technician, in performing such final verification, uses a  
332 technology that includes images of each drug that such advanced  
333 pharmacy technician reviews in performing such final verification. The  
334 provisions of this subdivision shall not apply to an institutional  
335 pharmacy.

336 (3) If an institutional pharmacy employs an advanced pharmacy  
337 technician, the institutional pharmacy shall, in addition to satisfying the  
338 requirements set forth in subdivision (1) of this subsection, not allow the  
339 advanced pharmacy technician to perform any final verification under  
340 subparagraph (A) of subdivision (2) of subsection (c) of this section  
341 unless such institutional pharmacy uses bar code scanning, or another  
342 technology or process approved by the department, at the point of  
343 administration to confirm accuracy in dispensing.

344 (e) The commissioner shall adopt regulations, in accordance with the  
345 provisions of chapter 54 of the general statutes, to implement the  
346 provisions of this section. Such regulations shall, at a minimum,  
347 establish: (1) Requirements for performance of the competency  
348 assessment required under subparagraph (B) of subdivision (5) of  
349 subsection (b) of this section; (2) ratios of pharmacists to advanced  
350 pharmacy technicians; and (3) additional requirements concerning the  
351 duties of advanced pharmacy technicians.

352       Sec. 3. (NEW) (*Effective October 1, 2024*) (a) Except for an individual  
353 who is otherwise registered with, or licensed by, the department under  
354 chapter 400j of the general statutes, each individual who will physically  
355 work in an area of a pharmacy or institutional pharmacy where  
356 controlled substances or other legend drugs are dispensed by, or under  
357 the supervision of, a pharmacist shall register with the department as a  
358 clerk in accordance with the provisions of this section. For the purposes  
359 of this section, an institutional pharmacy shall not be deemed to include  
360 any patient care area or automated prescription dispensing machine  
361 that is located outside of the area commonly known as the pharmacy.

362       (b) (1) The department shall register as a clerk any individual who  
363 submits to the department, in a form and manner prescribed by the  
364 commissioner, (A) a complete application for registration as a clerk, and  
365 (B) the application fee required in section 20-601 of the general statutes,  
366 as amended by this act.

367       (2) Each clerk registration issued under this section shall be issued in  
368 a form and manner prescribed by the commissioner, shall be valid for  
369 two years and may be renewed for successive two-year periods upon  
370 application and payment of the renewal fee required in section 20-601  
371 of the general statutes, as amended by this act.

372       (3) The department shall not refuse to issue any clerk registration  
373 under this section, or refuse to renew any clerk registration issued under  
374 this section, because the applicant for such registration or renewal has  
375 been convicted of a felony, unless such refusal is rendered in accordance  
376 with the provisions of section 46a-80 of the general statutes.

377       (c) A clerk may, under the direct supervision of a pharmacist, (1)  
378 handle dispensed drugs and deliver such drugs to patients, (2) collect  
379 patient demographic information, (3) collect a prescription number for  
380 the purposes of a refill, (4) deliver a drug to an automated prescription  
381 dispensing machine or other care-giving area within a care-giving  
382 institution or within a correctional or juvenile training institution, (5)  
383 perform the duties of a cashier, including, but not limited to, receiving

384 payment for dispensed drugs, (6) conduct inventory management, (7)  
385 return to stock any product used to fill a prescription but not sold to a  
386 patient, and (8) perform any other duties set forth in regulations  
387 adopted by the commissioner pursuant to subsection (e) of this section.

388 (d) No clerk shall (1) review any drug to determine whether such  
389 drug is an appropriate treatment, (2) verify the accuracy of the  
390 prescription data entered into an electronic data processing system used  
391 by a pharmacy, an original prescription, the contents of a prescription  
392 label or the contents of a prescription container, (3) perform any task  
393 that requires any professional pharmaceutical judgment, or (4)  
394 participate in order entry.

395 (e) The commissioner may adopt regulations, in accordance with the  
396 provisions of chapter 54 of the general statutes, to implement the  
397 provisions of this section, including, but not limited to, regulations  
398 establishing additional requirements for registration as a clerk.

399 Sec. 4. (NEW) (*Effective October 1, 2024*) (a) (1) A pharmacist or  
400 advanced pharmacy technician may, at the request of a patient, the  
401 patient's representative or the patient's prescribing practitioner,  
402 dispense to the patient compatible drugs in compliance packaging.

403 (2) (A) If a patient's prescribing practitioner modifies the patient's  
404 prescription or prescriptions by, among other things, issuing any new  
405 prescription or discontinuing or deprescribing any drug that was  
406 previously dispensed to the patient in compliance packaging, the  
407 pharmacy that first dispensed such previously dispensed drug in such  
408 compliance packaging may, at the request of such patient,  
409 representative or prescribing practitioner and if such pharmacy  
410 documents such modification in writing, (i) accept such compliance  
411 packaging from such patient or representative, (ii) receive and remove  
412 any drugs from such returned compliance packaging and redispense  
413 such drugs to such patient, and (iii) dispense any newly prescribed and  
414 compatible drugs in the redispensed compliance packaging.

415 (B) Any pharmacy that accepts any compliance packaging returned

416 under this subdivision shall do so exclusively to (i) dispense to the  
417 patient any compatible drugs that are newly prescribed to such patient,  
418 and (ii) redispense to the patient any drugs contained in such returned  
419 compliance packaging in the same quantities that were contained in  
420 such returned compliance packaging when such pharmacy accepted  
421 such returned compliance packaging.

422 (C) Each pharmacy that redispenses any drug contained in any  
423 compliance packaging returned under this subdivision shall redispense  
424 such drug to the patient in (i) compliance packaging that exclusively  
425 contains drugs currently prescribed to such patient, or (ii) a separate  
426 container that is labeled in accordance with the provisions of section 20-  
427 617 of the general statutes and subparagraph (D) of this subdivision.

428 (D) If a pharmacy accepts any compliance packaging returned under  
429 this subdivision and such returned compliance packaging contains one  
430 or more drugs that have been deprescribed, discontinued or have  
431 otherwise been deemed to be inappropriate for inclusion in compliance  
432 packaging, as determined by the patient's prescribing practitioner or a  
433 pharmacist, the pharmacy shall redispense such drugs to the patient in  
434 one or more separate containers, each of which shall (i) include not more  
435 than one drug type or dosage, and (ii) bear a label that includes the  
436 patient's name, the original prescription serial number or serial  
437 numbers, the drug name or names, the dosage form or forms, the  
438 quantity or quantities redispensed and instructions for use or disposal,  
439 as applicable, which instructions shall disclose, at a minimum, (I) the  
440 procedures for any lawfully available means of destroying such drug or  
441 drugs at home, and (II) the nearest location where such drug or drugs  
442 may be deposited for destruction, including, but not limited to, the  
443 nearest retail location allowed to accept such drug or drugs under the  
444 regulations adopted pursuant to section 20-576a of the general statutes.

445 (E) No pharmacy, pharmacist, pharmacy intern or advanced  
446 pharmacy technician shall return to a pharmacy's general inventory or  
447 regular stock any returned drug that was previously contained in any  
448 compliance packaging returned under this subdivision, unless

449 accepting such drug for return to the pharmacy's general inventory or  
450 regular stock is otherwise permitted or required by law.

451 (b) Compliance packaging shall:

452 (1) Exclusively contain (A) individual compartments that are tamper-  
453 evident, and (B) drugs that (i) are currently prescribed to a single patient  
454 pursuant to an order or prescription by the patient's prescribing  
455 practitioner, and (ii) dispensed or redispensed to a single patient by a  
456 pharmacist or an advanced pharmacy technician;

457 (2) Be labeled or relabeled by a pharmacist in accordance with the  
458 provisions of section 20-617 of the general statutes, except if the  
459 compliance packaging contains an opioid drug, as defined in section 20-  
460 14o of the general statutes, only one sticker or label shall be affixed to  
461 such compliance packaging pursuant to section 20-636 of the general  
462 statutes and not to each individual compartment contained in such  
463 compliance packaging;

464 (3) Be child-resistant unless the pharmacy provides to the patient, and  
465 the patient acknowledges and returns to the pharmacy, a waiver  
466 explaining that the drugs contained in the compliance packaging are not  
467 in a child-resistant container;

468 (4) Identify, on each individual compartment, the name and strength  
469 of the drug or drugs contained in such compartment;

470 (5) Not contain more than a ninety-day supply of any drug, as  
471 prescribed, except as otherwise provided in any applicable state or  
472 federal law; and

473 (6) Be compliant with all applicable provisions of the United States  
474 Pharmacopeia, as amended from time to time.

475 (c) (1) An individual compartment of compliance packaging may  
476 contain multiple prescribed drugs, provided:

477 (A) A pharmacist has determined that all drugs contained in such



478 compartment are compatible drugs;

479 (B) All drugs contained in such compartment are subject to the same  
480 instructions concerning time of administration; and

481 (C) No drug contained in such compartment has instructions for use  
482 that permit such drug to be used on an as needed basis.

483 (2) No controlled substance shall be contained in any compliance  
484 packaging that contains any other drug, unless such other drug is a  
485 controlled substance of the same drug type prescribed at a different  
486 dose.

487 (d) A pharmacy that provides compliance packaging services shall:

488 (1) Maintain an area dedicated to the preparation of drugs that are to  
489 be dispensed or redispensed in compliance packaging, which area shall  
490 include all equipment necessary to:

491 (A) Ensure that all compliance packaging is accurately prepared; and

492 (B) Prevent any contamination of such drugs;

493 (2) Maintain standard operating procedures:

494 (A) For the use of compliance packaging and associated equipment,  
495 which procedures shall include, at a minimum, provisions concerning  
496 (i) inspections of compliance packaging integrity, (ii) cleaning, (iii)  
497 labeling, (iv) dispensing and redispensing, (v) proper hand hygiene, (vi)  
498 quarantine, and (vii) handling of dispensed drugs that are removed  
499 from compliance packaging and redispensed to patients in the manner  
500 set forth in subdivision (2) of subsection (a) of this section; and

501 (B) That specify which drugs (i) are not compatible drugs, (ii) are  
502 suitable to be dispensed or redispensed in compliance packaging, or (iii)  
503 require special consideration to be dispensed or redispensed in  
504 compliance packaging; and

505 (3) Maintain the following records:

506 (A) A record of all drugs that the pharmacy dispenses to a patient in  
507 compliance packaging, which record shall include at least the following  
508 for each such drug:

509 (i) The patient's name and address;

510 (ii) The identification number, if any, for the compliance packaging  
511 in which such pharmacy dispensed such drug, the date such compliance  
512 packaging was prepared, the initials of the individual who prepared  
513 such compliance packaging and the initials of the individual who  
514 performed a final verification for such compliance packaging;

515 (iii) The name, strength, lot number and national drug code number  
516 for such drug;

517 (iv) The serial number of the prescription for such drug; and

518 (v) A visual description of such drug;

519 (B) A record of all items of compliance packaging that the pharmacy  
520 accepts from a patient for return and redispensing to the patient in the  
521 manner set forth in subdivision (2) of subsection (a) of this section,  
522 which record shall include at least the following for each such item of  
523 compliance packaging:

524 (i) The patient's name and address;

525 (ii) The identification number, if any, for such item of compliance  
526 packaging;

527 (iii) The date on which such pharmacy accepted such item of  
528 compliance packaging for return and redispensing in such manner;

529 (iv) The name of the pharmacist or pharmacy technician who  
530 documented the return of such item of compliance packaging; and

531 (v) The name, formulation and quantity of each drug contained in  
532 such item of compliance packaging when such pharmacy accepted such  
533 item of compliance packaging for return and redispensing in such

534 manner, including a designation disclosing whether any such drug was  
535 deprescribed if the patient's prescribing practitioner has discontinued  
536 the prescription;

537 (C) A record of all items of compliance packaging in which the  
538 pharmacy redispenses any drug to a patient in the manner set forth in  
539 subdivision (2) of subsection (a) of this section, which record shall  
540 include at least the following for each such item of compliance  
541 packaging:

542 (i) The patient's name and address;

543 (ii) The identification number, if any, for such item of compliance  
544 packaging;

545 (iii) The date such item of compliance packaging was prepared for  
546 redispensing in such manner;

547 (iv) The serial number of the prescription for each drug redispensed  
548 in such item of compliance packaging in such manner;

549 (v) The name, formulation and quantity of each drug redispensed in  
550 such item of compliance packaging in such manner;

551 (vi) The name or initials of the redispensing pharmacist;

552 (vii) The initials of the individual who prepared such item of  
553 compliance packaging for redispensing in such manner; and

554 (viii) The initials of the individual who performed a final verification  
555 for such item of compliance packaging for redispensing in such manner;  
556 and

557 (D) A record of all drugs that the pharmacy redispenses to a patient  
558 in any container, other than compliance packaging, in the manner set  
559 forth in subdivision (2) of subsection (a) of this section, which record  
560 shall include at least the following for each such drug:

561 (i) The patient's name and address;

562 (ii) The date such drug was prepared for redispensing in such  
563 container in such manner;

564 (iii) The serial number of the prescription for such drug;

565 (iv) The name and formulation of such drug and the quantity of such  
566 drug that was redispensed in such container in such manner; and

567 (v) The name or initials of the redispensing pharmacist.

568 (e) Each pharmacy shall maintain all records that such pharmacy is  
569 required to maintain pursuant to this section for a period of at least three  
570 years. Not later than forty-eight hours after the department requests that  
571 a pharmacy disclose a copy of any record the pharmacy is required to  
572 maintain pursuant to this section, such pharmacy shall disclose such  
573 copy to the department in electronic form or, if such pharmacy is unable  
574 to disclose such copy in electronic form, in paper form.

575 (f) The commissioner may adopt regulations, in accordance with the  
576 provisions of chapter 54 of the general statutes, to implement the  
577 provisions of this section.

578 Sec. 5. Subsection (a) of section 20-579 of the general statutes is  
579 repealed and the following is substituted in lieu thereof (*Effective October*  
580 *1, 2024*):

581 (a) The commission may refuse to authorize the issuance of a  
582 temporary permit to practice pharmacy, may refuse to authorize the  
583 issuance or renewal of a license to practice pharmacy, a license to  
584 operate a pharmacy or a registration of a pharmacy intern or pharmacy  
585 technician, and may revoke, suspend or place conditions on a license or  
586 temporary permit to practice pharmacy, a license to operate a pharmacy,  
587 or a registration of a pharmacy intern or a pharmacy technician, and  
588 may assess a civil penalty of up to one thousand dollars per violation of  
589 any provision of this chapter or take other action permitted in  
590 subdivision (7) of section 21a-7 if the applicant or holder of the license,  
591 temporary permit or registration: (1) Has violated a statute or regulation

592 relating to drugs, devices or the practice of pharmacy of this state, any  
593 state of the United States, the United States, the District of Columbia, the  
594 Commonwealth of Puerto Rico, any territory or insular possession  
595 subject to the jurisdiction of the United States or a foreign jurisdiction;  
596 (2) has been convicted of violating any criminal statute relating to drugs,  
597 devices or the practice of pharmacy of this state, any state of the United  
598 States, the United States, the District of Columbia, the Commonwealth  
599 of Puerto Rico, any territory or insular possession subject to the  
600 jurisdiction of the United States or a foreign jurisdiction; (3) has been  
601 disciplined by, or is the subject of pending disciplinary action or an  
602 unresolved complaint before, the duly authorized pharmacy  
603 disciplinary agency of any state of the United States, the United States,  
604 the District of Columbia, the Commonwealth of Puerto Rico, any  
605 territory or insular possession subject to the jurisdiction of the United  
606 States or a foreign jurisdiction; (4) has been refused a license or  
607 registration or renewal of a license or registration by any state of the  
608 United States, the United States, the District of Columbia, the  
609 Commonwealth of Puerto Rico, any territory or insular possession  
610 subject to the jurisdiction of the United States or a foreign jurisdiction  
611 based on grounds that are similar to grounds on which Connecticut  
612 could refuse to issue or renew such a license or registration; (5) has  
613 illegally possessed, diverted, sold or dispensed drugs or devices; (6)  
614 abuses or excessively uses drugs, including alcohol; (7) has made false,  
615 misleading or deceptive representations to the public or the  
616 commission; (8) has maintained exclusive telephone lines to, has  
617 maintained exclusive electronic communication with, or has exclusive  
618 access to computers located in offices of prescribing practitioners,  
619 nursing homes, clinics, hospitals or other health care facilities; (9) has  
620 substituted drugs or devices except as permitted in section 20-619; (10)  
621 has accepted, for return to regular stock, any drug already dispensed in  
622 good faith or delivered from a pharmacy, and exposed to possible and  
623 uncontrolled contamination or substitution; (11) has accepted, for return  
624 to general inventory or regular stock, any drug sold or delivered to a  
625 patient, unless accepting such drug for return to general inventory or  
626 regular stock is otherwise permitted or required by law; (12) has split

627 fees for professional services, including a discount or rebate, with a  
628 prescribing practitioner or an administrator or owner of a nursing home,  
629 hospital or other health care facility; [(12)] (13) has entered into an  
630 agreement with a prescribing practitioner or an administrator or owner  
631 of a nursing home, hospital or other health care facility for the  
632 compounding or dispensing of secret formula or coded prescriptions;  
633 [(13)] (14) has performed or been a party to a fraudulent or deceitful  
634 practice or transaction; [(14)] (15) has presented to the commission a  
635 diploma, license or certificate illegally or fraudulently obtained, or  
636 obtained from a college or school of pharmacy not approved by the  
637 commission; [(15)] (16) has performed incompetent or negligent work;  
638 [(16)] (17) has falsified a continuing education document submitted to  
639 the commission or department or a certificate retained in accordance  
640 with the provisions of subsection (d) of section 20-600; [(17)] (18) has  
641 permitted a person not licensed to practice pharmacy in this state to  
642 practice pharmacy in violation of section 20-605, to use a pharmacist  
643 license or pharmacy display document in violation of section 20-608, or  
644 to use words, displays or symbols in violation of section 20-609; [(18)]  
645 (19) has failed to maintain the entire pharmacy premises, its components  
646 and contents in a clean, orderly and sanitary condition; [(19)] (20) has  
647 failed to demonstrate adherence to applicable provisions of United  
648 States Pharmacopeia, Chapter 797, Pharmaceutical Compounding -  
649 Sterile Preparations, as amended from time to time; or [(20)] (21) has  
650 failed to demonstrate adherence to applicable provisions of United  
651 States Pharmacopeia, Chapter 795, Pharmaceutical Compounding -  
652 Nonsterile Preparations, as amended from time to time.

653 Sec. 6. Subsections (a) to (c), inclusive, of section 20-598a of the  
654 general statutes are repealed and the following is substituted in lieu  
655 thereof (*Effective October 1, 2024*):

656 (a) No person shall act as a pharmacy technician unless registered  
657 with, or certified with, the department, except an individual who is  
658 enrolled in an accredited pharmacy technician education program may  
659 engage in the duties of a pharmacy technician, as part of the curriculum  
660 of such program, under the direct supervision of a pharmacist who is an

661 instructor for such program.

662 (b) The department shall [, upon authorization of the commission,]  
663 register as a pharmacy technician any person who presents evidence  
664 satisfactory to the department that such person is qualified to perform,  
665 under the [direct] supervision of a pharmacist, routine functions in the  
666 dispensing of drugs that do not require the use of professional  
667 judgment. The qualifications for registration as a pharmacy technician  
668 under this section shall be in accordance with (1) the standards of an  
669 institutional pharmacy, a care-giving institution or a correctional or  
670 juvenile training institution, in the case of employment in any such  
671 pharmacy or institution, or (2) the standards established by regulation  
672 adopted by the commissioner in accordance with the provisions of  
673 chapter 54, in the case of employment in a pharmacy. [As used in this  
674 subsection, "direct supervision" means a supervising pharmacist (A) is  
675 physically present in the area or location where the pharmacy technician  
676 is performing routine drug dispensing functions, and (B) conducts  
677 in-process and final checks on the pharmacy technician's performance.]

678 (c) The department shall [, upon authorization of the commission,]  
679 certify as a pharmacy technician any person who meets the  
680 requirements for registration as a pharmacy technician, pursuant to  
681 subsection (b) of this section, and who holds a certification from the  
682 Pharmacy Technician Certification Board or any other equivalent  
683 pharmacy technician certification program approved by the  
684 department.

685 Sec. 7. Section 20-601 of the 2024 supplement to the general statutes  
686 is repealed and the following is substituted in lieu thereof (*Effective*  
687 *October 1, 2024*):

688 The department shall collect the following nonrefundable fees:

689 (1) The fee for issuance of a pharmacist license is two hundred  
690 dollars, payable at the date of application for the license.

691 (2) The fee for renewal of a pharmacist license is the professional

692 services fee for class A, as defined in section 33-182l. Before the  
693 commission or commissioner grants a license to an applicant who has  
694 not held a license authorized by the commission or commissioner within  
695 five years of the date of application, the applicant shall pay the fee  
696 required in subdivision (1) of this section.

697 (3) The fee for issuance of a pharmacy license is seven hundred fifty  
698 dollars.

699 (4) The fee for renewal of a pharmacy license is one hundred ninety  
700 dollars.

701 (5) The late fee for an application for renewal of a license to practice  
702 pharmacy, a pharmacy license or a permit to sell nonlegend drugs is the  
703 amount set forth in section 21a-4.

704 (6) The fee for notice of a change in officers or directors of a  
705 [corporation] business entity holding a pharmacy license is sixty dollars  
706 for each pharmacy license held. A late fee for failing to give such notice  
707 within ten days of the change is fifty dollars in addition to the fee for  
708 notice.

709 (7) The fee for filing notice of a change in name, ownership or  
710 management of a pharmacy is ninety dollars. A late fee for failing to give  
711 such notice within ten days of the change is fifty dollars in addition to  
712 the fee for notice.

713 (8) The fee for application for registration as a pharmacy intern is  
714 sixty dollars.

715 (9) The fee for application for a permit to sell nonlegend drugs is one  
716 hundred forty dollars.

717 (10) The fee for renewal of a permit to sell nonlegend drugs is one  
718 hundred dollars.

719 (11) The late fee for failing to notify the [commission] department of  
720 a change of ownership, name or location of the premises of a permit to



721 sell nonlegend drugs within five days of the change is twenty dollars.

722 (12) The fee for issuance of a nonresident pharmacy certificate of  
723 registration is seven hundred fifty dollars.

724 (13) The fee for renewal of a nonresident pharmacy certificate of  
725 registration is one hundred ninety dollars.

726 (14) The fee for notice of a change in officers or directors of a  
727 [corporation] business entity holding a nonresident pharmacy  
728 certificate of registration is sixty dollars for each pharmacy license held.  
729 A late fee for failing to give such notice within ten days of the change is  
730 fifty dollars, in addition to the fee for notice.

731 (15) The fee for filing notice of a change in name, ownership or  
732 management of a nonresident pharmacy is ninety dollars. A late fee for  
733 failing to give such notice within ten days of the change is fifty dollars,  
734 in addition to the fee for notice.

735 (16) The fee for application for registration as a pharmacy technician  
736 is one hundred dollars.

737 (17) The fee for renewal of a registration as a pharmacy technician is  
738 fifty dollars.

739 (18) The fee for application for designation as an advanced pharmacy  
740 technician is twenty-five dollars, which fee shall be in addition to the fee  
741 required in subdivision (16) of this section.

742 (19) The fee for renewal of a designation as an advanced pharmacy  
743 technician is twenty-five dollars, which fee shall be in addition to the fee  
744 required in subdivision (17) of this section.

745 ~~[(18)]~~ (20) The fee for issuance of a temporary permit to practice  
746 pharmacy is two hundred dollars.

747 (21) The fee for application for registration, and renewal of a  
748 registration, as a clerk is twenty-five dollars.

749 Sec. 8. Section 20-601 of the 2024 supplement to the general statutes,  
750 as amended by section 7 of this act, is repealed and the following is  
751 substituted in lieu thereof (*Effective July 1, 2025*):

752 The department shall collect the following nonrefundable fees:

753 (1) The fee for issuance of a pharmacist license is two hundred  
754 dollars, payable at the date of application for the license.

755 (2) The fee for renewal of a pharmacist license is [the professional  
756 services fee for class A, as defined in section 33-182] one hundred five  
757 dollars. Before the commission or commissioner grants a license to an  
758 applicant who has not held a license authorized by the commission or  
759 commissioner within five years of the date of application, the applicant  
760 shall pay the fee required in subdivision (1) of this section. On or before  
761 the last day of January, April, July and October in each year, the  
762 commissioner shall transfer five dollars of each renewal fee collected  
763 pursuant to this subdivision to the pharmacy professional assistance  
764 program account established in section 20-638c.

765 (3) The fee for issuance of a pharmacy license is seven hundred fifty  
766 dollars.

767 (4) The fee for renewal of a pharmacy license is one hundred ninety  
768 dollars.

769 (5) The late fee for an application for renewal of a license to practice  
770 pharmacy, a pharmacy license or a permit to sell nonlegend drugs is the  
771 amount set forth in section 21a-4.

772 (6) The fee for notice of a change in officers or directors of a business  
773 entity holding a pharmacy license is sixty dollars for each pharmacy  
774 license held. A late fee for failing to give such notice within ten days of  
775 the change is fifty dollars in addition to the fee for notice.

776 (7) The fee for filing notice of a change in name, ownership or  
777 management of a pharmacy is ninety dollars. A late fee for failing to give  
778 such notice within ten days of the change is fifty dollars in addition to

779 the fee for notice.

780 (8) The fee for application for registration as a pharmacy intern is  
781 [sixty dollars] sixty-five dollars. On or before the last day of January,  
782 April, July and October in each year, the commissioner shall transfer  
783 five dollars of each fee collected pursuant to this subdivision to the  
784 pharmacy professional assistance program account established in  
785 section 20-638c.

786 (9) The fee for application for a permit to sell nonlegend drugs is one  
787 hundred forty dollars.

788 (10) The fee for renewal of a permit to sell nonlegend drugs is one  
789 hundred dollars.

790 (11) The late fee for failing to notify the department of a change of  
791 ownership, name or location of the premises of a permit to sell  
792 nonlegend drugs within five days of the change is twenty dollars.

793 (12) The fee for issuance of a nonresident pharmacy certificate of  
794 registration is seven hundred fifty dollars.

795 (13) The fee for renewal of a nonresident pharmacy certificate of  
796 registration is one hundred ninety dollars.

797 (14) The fee for notice of a change in officers or directors of a business  
798 entity holding a nonresident pharmacy certificate of registration is sixty  
799 dollars for each pharmacy license held. A late fee for failing to give such  
800 notice within ten days of the change is fifty dollars, in addition to the fee  
801 for notice.

802 (15) The fee for filing notice of a change in name, ownership or  
803 management of a nonresident pharmacy is ninety dollars. A late fee for  
804 failing to give such notice within ten days of the change is fifty dollars,  
805 in addition to the fee for notice.

806 (16) The fee for application for registration as a pharmacy technician  
807 is one hundred dollars.

808 (17) The fee for renewal of a registration as a pharmacy technician is  
809 fifty dollars.

810 (18) The fee for application for designation as an advanced pharmacy  
811 technician is twenty-five dollars, which fee shall be in addition to the fee  
812 required in subdivision (16) of this section.

813 (19) The fee for renewal of a designation as an advanced pharmacy  
814 technician is twenty-five dollars, which fee shall be in addition to the fee  
815 required in subdivision (17) of this section.

816 (20) The fee for issuance of a temporary permit to practice pharmacy  
817 is two hundred dollars.

818 (21) The fee for application for registration, and renewal of a  
819 registration, as a clerk is twenty-five dollars.

820 Sec. 9. Section 20-633 of the 2024 supplement to the general statutes  
821 is repealed and the following is substituted in lieu thereof (*Effective*  
822 *October 1, 2024*):

823 (a) (1) Any person licensed as a pharmacist under part II of this  
824 chapter may order, prescribe and administer:

825 (A) Any vaccine, approved or authorized by the United States Food  
826 and Drug Administration that is listed on the National Centers for  
827 Disease Control and Prevention's [Adult Immunization Schedule] age-  
828 appropriate immunization schedule, to any patient who is: (i) Eighteen  
829 years of age or older; or (ii) at least twelve years of age but younger than  
830 eighteen years of age with (I) the consent of such patient's parent, legal  
831 guardian or other person having legal custody of such patient, or (II)  
832 proof that such patient is an emancipated minor; [.]

833 (B) Any vaccine not included on the National Centers for Disease  
834 Control and Prevention's Adult Immunization Schedule to any patient  
835 who is eighteen years of age or older, provided the vaccine  
836 administration instructions for such vaccine are available on the  
837 National Centers for Disease Control and Prevention's Internet web site;

838 and

839 (C) Any vaccine pursuant to a verbal or written prescription of a  
840 prescribing practitioner for a specific patient.

841 (2) A pharmacist shall make a reasonable effort to review a patient's  
842 vaccination history to prevent any inappropriate use of a requested  
843 vaccine.

844 (3) All vaccines administered pursuant to this section shall be  
845 administered in accordance with the: (A) Vaccine manufacturer's  
846 package insert or the orders of a prescribing practitioner; and (B)  
847 regulations adopted pursuant to subsection (d) of this section.

848 (4) A pharmacist may delegate to an advanced pharmacy technician  
849 the pharmacist's authority to administer a vaccine described in  
850 subparagraph (A) of subdivision (1) of this subsection to a patient  
851 described in said subparagraph, provided the advanced pharmacy  
852 technician administers the vaccine: (A) Under the direct supervision of  
853 such pharmacist; and (B) in accordance with the provisions of this  
854 section and the regulations adopted pursuant to subsection (d) of this  
855 section.

856 (b) A pharmacist who has completed the training required in  
857 regulations adopted pursuant to subsection (d) of this section may  
858 administer an epinephrine cartridge injector, as defined in section 19a-  
859 909, to a patient whom the pharmacist reasonably believes, based on  
860 such pharmacist's knowledge and training, is experiencing anaphylaxis,  
861 regardless of whether such patient has a prescription for an epinephrine  
862 cartridge injector. Such pharmacist, or such pharmacist's designee, shall  
863 call the 9-1-1 emergency telephone number either before or immediately  
864 after such pharmacist administers the epinephrine cartridge injector to  
865 such patient. Such pharmacist shall document the date, time and  
866 circumstances in which such pharmacist administered such epinephrine  
867 cartridge injector, and maintain such documentation for at least three  
868 years.

869 (c) (1) A certified and registered pharmacy technician may administer  
870 a vaccine to a patient at a pharmacy if: (A) The managing pharmacist of  
871 such pharmacy is authorized to administer vaccines under this section;  
872 and (B) such pharmacy technician (i) has successfully completed a  
873 course of hands-on training, certified by the American Council for  
874 Pharmacy Education, concerning the administration of vaccines, (ii) has  
875 been trained at such pharmacy regarding the process for administering  
876 vaccines to patients at such pharmacy, (iii) successfully completes at  
877 least one hour of annual continuing education concerning  
878 immunization, (iv) has been evaluated by the managing pharmacist of  
879 such pharmacy, and (v) administers such vaccine at the direction of the  
880 pharmacist on duty at such pharmacy.

881 (2) During the period beginning on September first and ending on  
882 March thirty-first of the succeeding calendar year, a certified and  
883 registered pharmacy technician shall not count toward the pharmacist-  
884 to-technician ratio set forth in section 20-576-33 of the regulations of  
885 Connecticut state agencies if such pharmacy technician: (A) Is  
886 authorized to administer vaccines under this section; and (B) exclusively  
887 performs duties related to the administration of vaccines during such  
888 period.

889 (d) (1) The Commissioner of Consumer Protection, in consultation  
890 with the Commissioner of Public Health and the Commission of  
891 Pharmacy, shall adopt regulations, in accordance with the provisions of  
892 chapter 54, to implement the provisions of this section. Such regulations  
893 shall: [(1)] (A) Require any pharmacist who administers a vaccine  
894 pursuant to this section to successfully complete an immunization  
895 training program for pharmacists; [(2)] (B) define the basic requirements  
896 of such training program, which shall include training and instruction  
897 in pre-administration education and screening, vaccine storage and  
898 handling, subcutaneous and intramuscular injections, recordkeeping,  
899 vaccine safety, cardiopulmonary resuscitation, basic cardiac life support  
900 and adverse event reporting; [(3)] (C) identify qualifying training  
901 programs, which are accredited by the National Centers for Disease  
902 Control Prevention, the Accreditation Council for Pharmacy Education

903 or another appropriate national accrediting body; and [(4)] (D) establish  
904 a system of control and reporting.

905 (2) The Commissioner of Consumer Protection may amend the  
906 regulations adopted pursuant to subdivision (1) of this subsection, in  
907 accordance with the provisions of chapter 54, to: (A) Establish additional  
908 requirements concerning delegations by pharmacists to advanced  
909 pharmacy technicians under this section; and (B) the administration of  
910 vaccines by advanced pharmacy technicians under this section.

911 Sec. 10. Section 20-633f of the 2024 supplement to the general statutes  
912 is repealed and the following is substituted in lieu thereof (*Effective*  
913 *October 1, 2024*):

914 (a) For the purposes of this section:

915 (1) "COVID-19" means the respiratory disease designated by the  
916 World Health Organization on February 11, 2020, as coronavirus 2019,  
917 and any related mutation thereof recognized by said organization;

918 (2) "COVID-19-related test" means any laboratory test, or series of  
919 laboratory tests, for any virus, antibody, antigen or etiologic agent  
920 thought to cause, or indicate the presence of, COVID-19;

921 (3) "HIV-related prophylaxis" means any drug approved by the  
922 federal Food and Drug Administration or any successor agency as a pre-  
923 exposure or post-exposure prophylaxis for the human  
924 immunodeficiency virus;

925 (4) "HIV-related test" has the same meaning as provided in section  
926 19a-7o; and

927 (5) "Influenza-related test" means any laboratory test, or series of  
928 laboratory tests, for any virus, antibody, antigen or etiologic agent  
929 thought to cause, or indicate the presence of, influenza disease.

930 (b) (1) Any pharmacist licensed under this chapter may order, and  
931 administer to a patient, a COVID-19-related test or influenza-related test

932 if: (A) Such pharmacist (i) is employed by a pharmacy that has  
933 submitted to the Department of Public Health a complete clinical  
934 laboratory improvement amendment application for certification for the  
935 COVID-19-related test or influenza-related test and the Department of  
936 Public Health has approved such application, and (ii) has completed any  
937 training required by the Department of Consumer Protection; and (B)  
938 the patient is (i) eighteen years of age or older, or (ii) at least twelve years  
939 of age but younger than eighteen years of age with (I) the consent of  
940 such patient's parent, legal guardian or other person having legal  
941 custody of such patient, or (II) proof that such patient is an emancipated  
942 minor.

943 (2) Any pharmacist licensed under this chapter may order, and  
944 administer to a patient, a COVID-19-related test or influenza-related test  
945 if: (A) Such pharmacist is employed by a hospital; and (B) the patient is  
946 (i) eighteen years of age or older, or (ii) at least twelve years of age but  
947 younger than eighteen years of age with (I) the consent of such patient's  
948 parent, legal guardian or other person having legal custody of such  
949 patient, or (II) proof that such patient is an emancipated minor.

950 (3) Any pharmacist licensed under this chapter may delegate to an  
951 advanced pharmacy technician the pharmacist's authority to administer  
952 to a patient a COVID-19-related test or influenza-related test under this  
953 subsection if: (A) The advanced pharmacy technician has completed any  
954 training required by the Department of Consumer Protection  
955 concerning the proper administration of the COVID-19-related test or  
956 influenza-related test; and (B) the advanced pharmacy technician  
957 administers the COVID-19-related test or influenza-related test (i) under  
958 the direct supervision of such pharmacist, and (ii) in accordance with  
959 the provisions of this section and the regulations adopted pursuant to  
960 subsection (g) of this section.

961 (c) (1) On or after the adoption of regulations pursuant to subsection  
962 (g) of this section, any pharmacist licensed under this chapter may  
963 order, and administer to a patient, an HIV-related test if: (A) Such  
964 pharmacist (i) is employed by a pharmacy that has submitted to the



965 Department of Public Health a complete clinical laboratory  
966 improvement amendment application for certification for the HIV-  
967 related test and the Department of Public Health has approved such  
968 application, and (ii) has completed the training required under  
969 regulations adopted pursuant to subsection (g) of this section; and (B)  
970 the patient is (i) eighteen years of age or older, or (ii) at least twelve years  
971 of age but younger than eighteen years of age with (I) the consent of  
972 such patient's parent, legal guardian or other person having legal  
973 custody of such patient, or (II) proof that such patient is an emancipated  
974 minor.

975 (2) On or after the adoption of regulations pursuant to subsection (g)  
976 of this section, any pharmacist licensed under this chapter may order,  
977 and administer to a patient, an HIV-related test if: (A) Such pharmacist  
978 is employed by a hospital; and (B) the patient is (i) eighteen years of age  
979 or older, or (ii) at least twelve years of age but younger than eighteen  
980 years of age and such pharmacist has obtained (I) the consent of such  
981 patient's parent, legal guardian or other person having legal custody of  
982 such patient, or (II) proof that such patient is an emancipated minor.

983 (3) Any pharmacist licensed under this chapter may delegate to an  
984 advanced pharmacy technician the pharmacist's authority to administer  
985 to a patient an HIV-related test under this subsection and the  
986 regulations adopted pursuant to subsection (g) of this section if: (A) The  
987 advanced pharmacy technician has completed any training required by  
988 the Department of Consumer Protection concerning the proper  
989 administration of the HIV-related test; and (B) the advanced pharmacy  
990 technician administers the HIV-related test (i) under the direct  
991 supervision of such pharmacist, and (ii) in accordance with the  
992 provisions of this section and the regulations adopted pursuant to  
993 subsection (g) of this section.

994 (d) (1) If a pharmacist orders and administers, or if a pharmacist  
995 orders and an advanced pharmacy technician working under the  
996 pharmacist's direct supervision administers, a COVID-19-related test or  
997 influenza-related test under subsection (b) of this section, or an HIV-

998 related test under subsection (c) of this section, the pharmacist shall: [(1)]  
999 (A) Provide the results of such test to [(A)] (i) the patient, in writing,  
1000 [(B)] (ii) the patient's primary care provider, if the patient identifies any  
1001 such primary care provider, and [(C)] (iii) the Commissioner of  
1002 Consumer Protection or said commissioner's designee, upon request by  
1003 said commissioner or such designee; [(2)] (B) report the results of such  
1004 test to the director of health of the town, city or borough in which such  
1005 case resides and to the Department of Public Health in the manner set  
1006 forth in section 19a-215 and applicable regulations; and [(3)] (C)  
1007 maintain a record of the results of such test for three years.

1008 (2) No pharmacist shall delegate to an advanced pharmacy technician  
1009 the pharmacist's duty to provide to the patient the results of: (A) A  
1010 COVID-19-related test or influenza-related test ordered and  
1011 administered under subsection (b) of this section; or (B) an HIV-related  
1012 test ordered and administered under subsection (c) of this section.

1013 (e) (1) If a pharmacist orders and administers, or if a pharmacist  
1014 orders and an advanced pharmacy technician working under the  
1015 pharmacist's direct supervision administers, an HIV-related test under  
1016 subsection (c) of this section and the result of such test is negative, the  
1017 pharmacist may prescribe and dispense to the patient any HIV-related  
1018 prophylaxis according to the manufacturer's package insert, provided:  
1019 (A) Such pharmacist has completed the training required under the  
1020 regulations adopted pursuant to subsection (g) of this section; (B) such  
1021 patient satisfies the criteria established in such package insert; and (C)  
1022 such HIV-related prophylaxis is prescribed and dispensed in  
1023 accordance with all applicable requirements established in (i) this  
1024 section, (ii) this chapter, or (iii) any regulations adopted pursuant to  
1025 subsection (g) of this section or this chapter.

1026 (2) If a pharmacist prescribes any HIV-related prophylaxis under  
1027 subdivision (1) of this subsection, the pharmacist shall provide to the  
1028 Commissioner of Consumer Protection or the commissioner's designee,  
1029 upon request by said commissioner or such designee: (A) A copy of the  
1030 results of the HIV-related test described in subdivision (1) of this

1031 subsection; (B) prescription information maintained pursuant to this  
1032 chapter; and (C) any other documentation the commissioner may  
1033 require in regulations adopted pursuant to subsection (g) of this section.

1034 (f) Notwithstanding the provisions of section 1-210, all information a  
1035 pharmacist submits to the Department of Consumer Protection  
1036 pursuant to this section, or any regulation adopted pursuant to  
1037 subsection (g) of this section, shall be confidential. The department shall  
1038 use such information to perform the department's duties concerning  
1039 pharmacy, to ensure compliance with and enforce provisions of the  
1040 general statutes and regulations of Connecticut state agencies  
1041 concerning pharmacy and for no other purpose. If the department  
1042 brings an enforcement action and uses any such information as part of  
1043 such action, the department may disclose such information to the parties  
1044 to such action only if such disclosure is required by applicable law. No  
1045 such party shall further disclose such information except to a tribunal,  
1046 the Commission of Pharmacy, an administrative agency or a court with  
1047 jurisdiction over such action. Such tribunal, commission, agency or  
1048 court shall ensure that such information is subject to a qualified  
1049 protective order, as defined in 45 CFR 164.512(e), as amended from time  
1050 to time.

1051 (g) (1) The Commissioner of Consumer Protection, in consultation  
1052 with the Commissioner of Public Health, the Commission of Pharmacy,  
1053 a state-wide professional society representing the interests of physicians  
1054 practicing medicine in this state and a state-wide organization  
1055 representing the interests of health care professionals and scientists  
1056 specializing in the control and prevention of infectious diseases, shall  
1057 adopt regulations, in accordance with the provisions of chapter 54, to  
1058 implement the provisions of this section. Such regulations shall, at a  
1059 minimum: [(1)] (A) Ensure compliance with all applicable guidance  
1060 issued by the federal Centers for Disease Control and Prevention; [(2)]  
1061 (B) ensure that each HIV-related prophylaxis prescribed and dispensed  
1062 under subsection (e) of this section is prescribed and dispensed in  
1063 accordance with the approval the federal Food and Drug  
1064 Administration has granted for such HIV-related prophylaxis; [(3)] (C)

1065 establish permissible routes of administration; [(4)] (D) establish  
1066 prescription duration limits not to exceed [(A)] (i) sixty days for any pre-  
1067 exposure HIV-related prophylaxis, or [(B)] (ii) thirty days for any post-  
1068 exposure HIV-related prophylaxis; [(5)] (E) specify [(A)] (i) how  
1069 frequently a pharmacist shall provide treatment to a patient under this  
1070 section, [(B)] (ii) when a pharmacist providing treatment to a patient  
1071 under this section shall refer such patient to such patient's primary care  
1072 provider or any other health care provider identified by such patient,  
1073 and [(C)] (iii) the circumstances in which a pharmacist shall recommend  
1074 that a patient undergo screenings for sexually transmitted infections  
1075 other than the human immunodeficiency virus; [(6)] (F) establish  
1076 requirements concerning private areas for consultations between  
1077 pharmacists and patients; [(7)] (G) establish training requirements  
1078 concerning [(A)] (i) methods to obtain a patient's complete sexual  
1079 history, [(B)] (ii) delivering a positive HIV-related test result to a patient,  
1080 [(C)] (iii) referring a patient who has tested positive for the human  
1081 immunodeficiency virus to the services that are available to such  
1082 patient, and [(D)] (iv) using HIV-related prophylaxes for patients who  
1083 have tested negative for the human immunodeficiency virus; [(8)] (H)  
1084 identify qualifying training programs, which are accredited by the  
1085 National Centers for Disease Control and Prevention, the Accreditation  
1086 Council for Pharmacy Education or another appropriate national  
1087 accrediting body; and [(9)] (I) establish a system of control and  
1088 reporting.

1089 (2) The Commissioner of Consumer Protection may amend the  
1090 regulations adopted pursuant to subdivision (1) of this subsection, in  
1091 accordance with the provisions of chapter 54, to: (A) Establish additional  
1092 requirements concerning delegations by pharmacists to advanced  
1093 pharmacy technicians under this section; and (B) the administration of  
1094 COVID-19-related tests, influenza-related tests and HIV-related tests by  
1095 advanced pharmacy technicians under this section.

1096 Sec. 11. (*Effective from passage*) (a) There is established a task force to  
1097 study the impact of unannounced retail pharmacy closures. Such study  
1098 shall include, but need not be limited to, an examination of any available

1099 means of ensuring that patients are able to maintain access to their  
1100 prescriptions in the event of an unannounced retail pharmacy closure.

1101 (b) The task force shall consist of the following members:

1102 (1) Two appointed by the speaker of the House of Representatives;

1103 (2) Two appointed by the president pro tempore of the Senate;

1104 (3) One appointed by the majority leader of the House of  
1105 Representatives;

1106 (4) One appointed by the majority leader of the Senate;

1107 (5) One appointed by the minority leader of the House of  
1108 Representatives;

1109 (6) One appointed by the minority leader of the Senate;

1110 (7) The Commissioner of Consumer Protection, or the commissioner's  
1111 designee; and

1112 (8) Two persons appointed by the Governor.

1113 (c) Any member of the task force appointed under subdivision (1),  
1114 (2), (3), (4), (5) or (6) of subsection (b) of this section may be a member  
1115 of the General Assembly.

1116 (d) All initial appointments to the task force shall be made not later  
1117 than thirty days after the effective date of this section. Any vacancy shall  
1118 be filled by the appointing authority.

1119 (e) The speaker of the House of Representatives and the president pro  
1120 tempore of the Senate shall select the chairpersons of the task force from  
1121 among the members of the task force. Such chairpersons shall schedule  
1122 the first meeting of the task force, which shall be held not later than sixty  
1123 days after the effective date of this section.

1124 (f) The administrative staff of the joint standing committee of the

1125 General Assembly having cognizance of matters relating to consumer  
 1126 protection shall serve as administrative staff of the task force.

1127 (g) Not later than January 1, 2025, the task force shall submit a report  
 1128 on its findings and recommendations to the joint standing committee of  
 1129 the General Assembly having cognizance of matters relating to  
 1130 consumer protection, in accordance with the provisions of section 11-4a  
 1131 of the general statutes. The task force shall terminate on the date that it  
 1132 submits such report or January 1, 2025, whichever is later.

1133 Sec. 12. Section 259 of public act 23-204 is repealed. (*Effective October*  
 1134 *1, 2024*)"

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>October 1, 2024</i>	20-571
Sec. 2	<i>October 1, 2024</i>	New section
Sec. 3	<i>October 1, 2024</i>	New section
Sec. 4	<i>October 1, 2024</i>	New section
Sec. 5	<i>October 1, 2024</i>	20-579(a)
Sec. 6	<i>October 1, 2024</i>	20-598a(a) to (c)
Sec. 7	<i>October 1, 2024</i>	20-601
Sec. 8	<i>July 1, 2025</i>	20-601
Sec. 9	<i>October 1, 2024</i>	20-633
Sec. 10	<i>October 1, 2024</i>	20-633f
Sec. 11	<i>from passage</i>	New section
Sec. 12	<i>October 1, 2024</i>	Repealer section